Lilly said it plans to ask regulators to approve the drug by the end of 2025. View on euronews ...

Eli Lilly on Tuesday said the Phase 3 study of orforglipron in adults with obesity or overweight and type 2 diabetes met the primary and all key secondary endpoints at all three doses, showing ...

Eli Lilly stated that results from a late-stage trial of its pill variant of GLP-1 drugs met the requirements for global ...

A groundbreaking final stage trial showed users could lose more than 10 per cent of their weight after just over a year on ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to ...